Reagent Kit for Detection and Quantitative Determination of bcr-abl Chimeric Gene mRNA (M-bcr Variant) and abl Gene mRNA in Clinical Samples by PCR with Real-Time Hybridization-Fluorescent Detection

Reagent Kit for Detection and Quantitative Determination of bcr-abl Chimeric Gene mRNA (M-bcr Variant) and abl Gene mRNA in Clinical Samples by PCR with Real-Time Hybridization-Fluorescent Detection

This reagent kit is designed for the detection and quantitative determination of bcr-abl chimeric gene mRNA (M-bcr variant) and abl gene mRNA in clinical samples. The kit uses polymerase chain reaction (PCR) with real-time hybridization-fluorescent detection and is marketed as "AmpliSens® Leukosis Quant M-bcr-FRT" according to TU 9398-033-01897593-2007.

FRT Format

The kit is available in 1 configuration:

• RIBO-sol-D, variant 100
• PEBEPTA-L, variant 100
• AmpliSens, FRT variant

If your organization wants to sell medical equipment, medical products or medical consumables in Russia, for example, Reagent Kit for Detection and Quantitative Determination of bcr-abl Chimeric Gene mRNA (M-bcr Variant) and abl Gene mRNA in Clinical Samples by PCR with Real-Time Hybridization-Fluorescent Detection, then our information portal MEDCOMMERCE can help you with this. To do this, simply fill out the feedback form by clicking on the link FEEDBACK FORM.

The products posted on our website are approved for use in Russia by the state regulator Roszdravnadzor (Federal Service for Surveillance in Healthcare). The information is for informational purposes only.